Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis

Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatm...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Naglaa El-Gendy, Fathiya EL-Raey, Sherif Nassib, Noha Elsadany
Format: article
Langue:EN
Publié: Al-Azhar University, Faculty of Medicine (Damietta) 2020
Sujets:
direct acting antiviral drugs
end stage renal disease
hepatitis c
viral infection
hemodialysis
Medicine (General)
R5-920
Accès en ligne:https://doaj.org/article/d77cf999ebbc437a90bbcf7c9a2894ed
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/d77cf999ebbc437a90bbcf7c9a2894ed

Documents similaires